{"id":"W4304811002","doi":"10.51731/cjht.2022.464","title":"Lenvatinib and Pembrolizumab (Lenvima and Keytruda)","year":2022,"lang":"en","type":"article","venue":"Canadian Journal of Health Technologies","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"European Organisation for Research and Treatment of Cancer; Eisai Canada; Eisai; Memorial Sloan-Kettering Cancer Center","keywords":"Pembrolizumab; Lenvatinib; Reimbursement; Medicine; Internal medicine; Systemic therapy; Oncology; Intensive care medicine; Immunotherapy; Cancer; Political science","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00122364,0.0003403852,0.0003969489,0.001361526,0.0003041156,0.001316642,0.0004309268,0.0006662999,0.01609063],"category_scores_gemma":[0.002092038,0.0001437396,0.000778862,0.001167094,0.0003564323,0.0006930204,0.0004657368,0.0006618797,0.002488058],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002754679,"about_ca_system_score_gemma":0.00457008,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03577743,"about_ca_topic_score_gemma":0.1372366,"domain_scores_codex":[0.9991844,0.0002094075,0.0001003458,0.00007779043,0.0003397707,0.00008818434],"domain_scores_gemma":[0.9990637,0.0002067614,0.0002784269,0.00002780205,0.0003271735,0.00009615104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001137591,0.0001047201,0.002840317,0.006535879,0.0004193473,0.0001816016,0.00005412299,0.0001943802,0.003297059,0.005740587,0.1044865,0.8750079],"study_design_scores_gemma":[0.0004474607,0.001055196,0.01743258,0.003523675,0.0004799853,0.0007540315,0.0001102309,0.0001442267,0.002918267,0.0009231269,0.9721854,0.00002577821],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"other","genre_scores_codex":[0.01307213,0.7924158,0.00112514,0.01246054,0.001564284,0.000479949,0.005038844,0.0001712591,0.173672],"genre_scores_gemma":[0.1667649,0.661223,0.008377526,0.01375123,0.0009673273,0.0005732608,0.008651379,0.00006243352,0.1396289],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.03577743,"threshold_uncertainty_score":0.07113832,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02496382292737912,"score_gpt":0.2793609517246027,"score_spread":0.2543971287972235,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}